Medicus Pharma Clears FDA Hurdle for SkinJect® Study in Gorlin Syndrome — Medicus Pharma Ltd.

Event summary

FDA issued a 'Study May Proceed' letter on July 23, 2026, allowing Medicus Pharma to initiate its Phase 2b registrational study for SkinJect® in Gorlin Syndrome patients.
The study will enroll up to 50 patients with multiple basal cell carcinomas (BCCs) and evaluate the efficacy and safety of SkinJect® 200 mcg.
FDA recommendations strengthened the protocol, including baseline biopsy confirmation, revised primary efficacy endpoints, and extended follow-up to assess treatment durability.
SkinJect® is a dissolvable microneedle-array patch delivering doxorubicin directly into BCC lesions, aiming to minimize systemic drug exposure.

The big picture

Medicus Pharma's FDA clearance marks a critical step in developing SkinJect® as a non-surgical treatment option for Gorlin Syndrome, a condition characterized by multiple BCCs requiring repeated surgeries. The study's success could set a new standard for localized precision therapy in rare genetic disorders, addressing a significant unmet medical need. The strategic focus on generating decision-grade clinical data aims to attract potential pharmaceutical partners, enhancing Medicus' valuation and market positioning.

What we're watching

Regulatory Alignment: Whether Medicus can efficiently incorporate FDA's additional recommendations into the study protocol without significant delays.
Clinical Efficacy: The pace at which SkinJect® demonstrates robust clinical and histological clearance in Gorlin Syndrome patients, supporting its potential as a first-of-its-kind therapy.
Market Potential: How the successful advancement of SkinJect® could position Medicus for strategic partnerships or licensing deals in the rare disease space.